1
|
Erol C, Yekedüz E, Tural D, Karakaya S, Şentürk Öztaş N, Uçar G, Kılıçkap S, Ertürk İ, Sever ÖN, Arslan Ç, Küçükarda A, Can O, Balvan Ö, Yazgan SC, Özgüroğlu M, Öksüzoğlu B, Şendur MAN, Ürün Y. Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium. Urol Int 2023:1-7. [PMID: 36996793 DOI: 10.1159/000528994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2022] [Accepted: 12/22/2022] [Indexed: 04/01/2023]
Abstract
INTRODUCTION We aimed to evaluate clinical features, prognostic factors, and treatment preferences in patients with non-clear cell renal cell carcinoma (nccRCC). METHODS Patients with metastatic nccRCC were selected from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) database. Clinical features, prognostic factors, and overall survival (OS) outcomes were investigated. RESULTS A total of 118 patients diagnosed with nccRCC were included in this study. The median age at diagnosis was 62 years (interquartile range: 56-69). Papillary (57.6%) and chromophobe tumors (12.7%) are common histologic subtypes. Sarcomatoid differentiation was present in 19.5% of all patients. When the patients were categorized according to the International Metastatic RCC Database Consortium (IMDC) risk scores, 66.9% of the patients were found to be in the intermediate or poor risk group. Approximately half of the patients (55.9%) received interferon in the first line. At the median follow-up of 53.2 months (95% confidence interval [CI]: 34.7-71.8), the median OS was 19.3 months (95% CI: 14.1-24.5). In multivariate analysis, lung metastasis (hazard ratio [HR]:2.22, 95% CI: 1.23-3.99) and IMDC risk score (HR: 2.35, 95% CI: 1.01-5.44 for intermediate risk; HR: 8.86, 95% CI: 3.47-22.61 for poor risk) were found to be independent prognostic factors. CONCLUSION In this study, survival outcomes are consistent with previous studies. The IMDC risk score and lung metastasis are the independent prognostic factors for OS. This is an area that needs research to better treat this group of patients and create new treatment options.
Collapse
Affiliation(s)
- Cihan Erol
- Department of Medical Oncology, Faculty of Medicine, Ankara Yıldırım Beyazıt University, Ankara, Turkey
| | - Emre Yekedüz
- Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey
- Ankara University Cancer Research Institute, Ankara, Turkey
| | - Deniz Tural
- Department of Medical Oncology, Bakirköy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul, Turkey
| | - Serdar Karakaya
- Medical Oncology Department, University of Health Sciences Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Ankara, Turkey
| | - Nihan Şentürk Öztaş
- Division of Medical Oncology, Cerrahpaşa Faculty of Medicine, İstanbul University-Cerrahpaşa, Istanbul, Turkey
| | - Gökhan Uçar
- Department of Medical Oncology, Ankara City Hospital, University of Health Sciences, Ankara, Turkey
| | - Saadettin Kılıçkap
- Department of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
- Department of Medical Oncology, Faculty of Medicine, İstinye University, Istanbul, Turkey
| | - İsmail Ertürk
- Department of Medical Oncology, Gülhane Education and Research Hospital, University of Health Sciences, Ankara, Turkey
| | - Özlem Nuray Sever
- Department of Medical Oncology, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey
| | - Çağatay Arslan
- Department of Medical Oncology, Faculty of Medicine, İzmir University of Economics, Izmir, Turkey
| | - Ahmet Küçükarda
- Department of Medical Oncology, Faculty of Medicine, Trakya University, Edirne, Turkey
| | - Orçun Can
- Department of Medical Oncology, Faculty of Medicine, İstinye University, Istanbul, Turkey
| | - Özlem Balvan
- Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey
| | - Satı Coşkun Yazgan
- Department of Internal Medicine, Faculty of Medicine, Ankara University, Ankara, Turkey
| | - Mustafa Özgüroğlu
- Division of Medical Oncology, Cerrahpaşa Faculty of Medicine, İstanbul University-Cerrahpaşa, Istanbul, Turkey
| | - Berna Öksüzoğlu
- Medical Oncology Department, University of Health Sciences Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Ankara, Turkey
| | - Mehmet Ali Nahit Şendur
- Department of Medical Oncology, Faculty of Medicine, Ankara Yıldırım Beyazıt University, Ankara, Turkey
| | - Yüksel Ürün
- Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey
- Ankara University Cancer Research Institute, Ankara, Turkey
| |
Collapse
|
2
|
Karacin C, Oksuzoglu B, Demirci A, Keskinkılıç M, Baytemür NK, Yılmaz F, Selvi O, Erdem D, Avşar E, Paksoy N, Demir N, Göksu SS, Türker S, Bayram E, Çelebi A, Yılmaz H, Kuzu ÖF, Kahraman S, Gökmen İ, Sakin A, Alkan A, Nayır E, Uğraklı M, Acar Ö, Ertürk İ, Demir H, Aslan F, Sönmez Ö, Korkmaz T, Celayir ÖM, Karadağ İ, Kayıkçıoğlu E, Şakalar T, Öktem İN, Eren T, Erul E, Mocan EE, Kalkan Z, Yıldırım N, Ergün Y, Akagündüz B, Karakaya S, Kut E, Teker F, Demirel BÇ, Karaboyun K, Almuradova E, Ünal OÜ, Oyman A, Işık D, Okutur K, Öztosun B, Gülbağcı BB, Kalender ME, Şahin E, Seyyar M, Özdemir Ö, Selçukbiricik F, Kanıtez M, Dede İ, Gümüş M, Gökmen E, Yaren A, Menekşe S, Ebinç S, Aksoy S, İmamoğlu Gİ, Altınbaş M, Çetin B, Uluç BO, Er Ö, Karadurmuş N, Erdoğan AP, Artaç M, Tanrıverdi Ö, Çiçin İ, Şendur MAN, Oktay E, Bayoğlu İV, Paydaş S, Aydıner A, Salim DK, Geredeli Ç, Yavuzşen T, Doğan M, Hacıbekiroğlu İ. Correction: Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy. BMC Cancer 2023; 23:192. [PMID: 36849943 PMCID: PMC9969671 DOI: 10.1186/s12885-023-10662-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/01/2023] Open
Affiliation(s)
- Cengiz Karacin
- Department of Medical Oncology, UHS Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey.
| | - Berna Oksuzoglu
- grid.413794.cDepartment of Medical Oncology, UHS Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey
| | - Ayşe Demirci
- grid.49746.380000 0001 0682 3030Department of Medical Oncology, Sakarya University, Sakarya, Turkey
| | - Merve Keskinkılıç
- grid.21200.310000 0001 2183 9022Department of Medical Oncology, Dokuz Eylül University, İzmir, Turkey
| | | | - Funda Yılmaz
- grid.413794.cDepartment of Medical Oncology, UHS Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey
| | - Oğuzhan Selvi
- Department of Medical Oncology, Okmeydanı Prof. Dr. Cemil Taşcıoğlu City Hospital, Istanbul, Turkey
| | - Dilek Erdem
- Department of Medical Oncology, VM Medical Park Hospital, Samsun, Turkey
| | - Esin Avşar
- grid.413819.60000 0004 0471 9397Department of Medical Oncology, Antalya Training and Research Hospital, Antalya, Turkey
| | - Nail Paksoy
- grid.9601.e0000 0001 2166 6619Department of Medical Oncology, Istanbul University Instıtue of Oncology, Istanbul, Turkey
| | - Necla Demir
- grid.413290.d0000 0004 0643 2189Department of Medical Oncology, Acıbadem Hospital, Kayseri, Turkey
| | - Sema Sezgin Göksu
- grid.29906.34Department of Medical Oncology, Akdeniz University, Antalya, Turkey
| | - Sema Türker
- Department of Medical Oncology, Zonguldak Hospital, Zonguldak, Turkey
| | - Ertuğrul Bayram
- grid.98622.370000 0001 2271 3229Department of Medical Oncology, Çukurova University, Adana, Turkey
| | - Abdüssamet Çelebi
- grid.414850.c0000 0004 0642 8921Department of Medical Oncology, Marmara University Pendik Training and Research Hospital, Istanbul, Turkey
| | - Hatice Yılmaz
- grid.34517.340000 0004 0595 4313Department of Medical Oncology, Adnan Menderes University, Aydın, Turkey
| | - Ömer Faruk Kuzu
- grid.512925.80000 0004 7592 6297Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey
| | - Seda Kahraman
- grid.512925.80000 0004 7592 6297Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey
| | - İvo Gökmen
- grid.411693.80000 0001 2342 6459Department of Medical Oncology, Trakya University, Edirne, Turkey
| | - Abdullah Sakin
- grid.411781.a0000 0004 0471 9346Department of Medical Oncology, Istanbul Medipol University Bahçelievler Hospital, Istanbul, Turkey
| | - Ali Alkan
- grid.411861.b0000 0001 0703 3794Department of Medical Oncology, Muğla Sıtkı Koçman University, Muğla, Turkey
| | - Erdinç Nayır
- Mersin Medical Park Hospital, Department of Medical Oncology, Mersin, Turkey
| | - Muzafer Uğraklı
- grid.411124.30000 0004 1769 6008Department of Medical Oncology, Necmettin Erbakan University, Konya, Turkey
| | - Ömer Acar
- grid.411688.20000 0004 0595 6052Department of Medical Oncology, Celal Bayar University, Manisa, Turkey
| | - İsmail Ertürk
- Department of Medical Oncology, Gülhane Training and Research Hospital, Ankara, Turkey
| | - Hacer Demir
- Department of Medical Oncology, Afyonkarahisar Health Sciences University Hospital, Afyonkarahisar, Turkey
| | - Ferit Aslan
- Department of Medical Oncology, Ankara Medical Park Hospital, Ankara, Turkey
| | - Özlem Sönmez
- grid.411117.30000 0004 0369 7552Department of Medical Oncology, Acıbadem University Maslak Hospital, Istanbul, Turkey
| | - Taner Korkmaz
- grid.411117.30000 0004 0369 7552Department of Medical Oncology, Acıbadem University Maslak Hospital, Istanbul, Turkey
| | - Özde Melisa Celayir
- grid.411117.30000 0004 0369 7552Department of Medical Oncology, Acıbadem University Maslak Hospital, Istanbul, Turkey
| | - İbrahim Karadağ
- grid.440466.40000 0004 0369 655XDepartment of Medical Oncology, Hitit University Hospital, Çorum, Turkey
| | - Erkan Kayıkçıoğlu
- grid.45978.37Department of Medical Oncology, Süleyman Demirel University Hospital, Isparta, Turkey
| | - Teoman Şakalar
- Department of Medical Oncology, Kahramanmaraş Necip Fazıl City Hospital, Kahramanmaraş, Turkey
| | - İlker Nihat Öktem
- Department of Medical Oncology, Ersin Arslan Training and Research Hospital, Gaziantep, Turkey
| | - Tülay Eren
- grid.413698.10000 0004 0419 0366Department of Medical Oncology, UHS Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
| | - Enes Erul
- grid.14442.370000 0001 2342 7339Department of Medical Oncology, Hacettepe University Instıtue of Oncology, Ankara, Turkey
| | - Eda Eylemer Mocan
- grid.7256.60000000109409118Department of Medical Oncology, Ankara University, Ankara, Turkey
| | - Ziya Kalkan
- grid.411690.b0000 0001 1456 5625Department of Medical Oncology, Dicle University, Diyarbakır, Turkey
| | - Nilgün Yıldırım
- grid.411320.50000 0004 0574 1529Department of Medical Oncology, Fırat University, Elazığ, Turkey
| | - Yakup Ergün
- Batman Training and Research Hospital, Batman, Turkey
| | - Baran Akagündüz
- grid.412176.70000 0001 1498 7262Department of Medical Oncology, Erzincan Binali Yıldırım University, Erzincan, Turkey
| | - Serdar Karakaya
- Department of Medical Oncology, Atatürk Pulmonary Diseases Hospital, Ankara, Turkey
| | - Engin Kut
- Department of Medical Oncology, Manisa City Hospital, Manisa, Turkey
| | - Fatih Teker
- grid.411549.c0000000107049315Department of Medical Oncology, Gaziantep University, Gaziantep, Turkey
| | - Burçin Çakan Demirel
- grid.411742.50000 0001 1498 3798Department of Medical Oncology, Pamukkale University, Denizli, Turkey
| | - Kubilay Karaboyun
- grid.412006.10000 0004 0369 8053Department of Medical Oncology, Namık Kemal University, Tekirdağ, Turkey
| | - Elvina Almuradova
- grid.8302.90000 0001 1092 2592Department of Medical Oncology, Ege University, İzmir, Turkey
| | - Olçun Ümit Ünal
- grid.414882.30000 0004 0643 0132UHS İzmir Tepecik Training and Research Hospital, İzmir, Turkey
| | - Abdilkerim Oyman
- grid.417018.b0000 0004 0419 1887Department of Medical Oncology, Ümraniye Training and Research Hospital, Istanbul, Turkey
| | - Deniz Işık
- Kocaeli Medical Park, Department of Medical Oncology, Kocaeli, Turkey
| | - Kerem Okutur
- grid.414854.8Department of Medical Oncology, Bahçelievler Memorial Hospital, Istanbul, Turkey
| | - Buğra Öztosun
- grid.411776.20000 0004 0454 921XDepartment of Medical Oncology, Istanbul Medeniyet University, Istanbul, Turkey
| | - Burcu Belen Gülbağcı
- grid.49746.380000 0001 0682 3030Department of Medical Oncology, Sakarya University, Sakarya, Turkey
| | | | - Elif Şahin
- grid.411105.00000 0001 0691 9040Department of Medical Oncology, Kocaeli University, Kocaeli, Turkey
| | - Mustafa Seyyar
- grid.411105.00000 0001 0691 9040Department of Medical Oncology, Kocaeli University, Kocaeli, Turkey
| | - Özlem Özdemir
- grid.414879.70000 0004 0415 690Xİzmir Bozyaka Training and Research Hospital, İzmir, Turkey
| | - Fatih Selçukbiricik
- grid.15876.3d0000000106887552Department of Medical Oncology, Koç University, Istanbul, Turkey
| | - Metin Kanıtez
- grid.413690.90000 0000 8653 4054Department of Medical Oncology, American Hospital, Istanbul, Turkey
| | - İsa Dede
- grid.14352.310000 0001 0680 7823Department of Medical Oncology, Mustafa Kemal University, Hatay, Turkey
| | - Mahmut Gümüş
- grid.411776.20000 0004 0454 921XDepartment of Medical Oncology, Istanbul Medeniyet University, Istanbul, Turkey
| | - Erhan Gökmen
- grid.8302.90000 0001 1092 2592Department of Medical Oncology, Ege University, İzmir, Turkey
| | - Arzu Yaren
- grid.411742.50000 0001 1498 3798Department of Medical Oncology, Pamukkale University, Denizli, Turkey
| | - Serkan Menekşe
- Department of Medical Oncology, Manisa City Hospital, Manisa, Turkey
| | - Senar Ebinç
- grid.411690.b0000 0001 1456 5625Department of Medical Oncology, Dicle University, Diyarbakır, Turkey
| | - Sercan Aksoy
- grid.14442.370000 0001 2342 7339Department of Medical Oncology, Hacettepe University Instıtue of Oncology, Ankara, Turkey
| | - Gökşen İnanç İmamoğlu
- grid.413698.10000 0004 0419 0366Department of Medical Oncology, UHS Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
| | - Mustafa Altınbaş
- grid.413698.10000 0004 0419 0366Department of Medical Oncology, UHS Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
| | - Bülent Çetin
- grid.45978.37Department of Medical Oncology, Süleyman Demirel University Hospital, Isparta, Turkey
| | - Başak Oyan Uluç
- grid.411117.30000 0004 0369 7552Department of Medical Oncology, Acıbadem University Maslak Hospital, Istanbul, Turkey
| | - Özlem Er
- grid.411117.30000 0004 0369 7552Department of Medical Oncology, Acıbadem University Maslak Hospital, Istanbul, Turkey
| | - Nuri Karadurmuş
- Department of Medical Oncology, Gülhane Training and Research Hospital, Ankara, Turkey
| | - Atike Pınar Erdoğan
- grid.411688.20000 0004 0595 6052Department of Medical Oncology, Celal Bayar University, Manisa, Turkey
| | - Mehmet Artaç
- grid.411124.30000 0004 1769 6008Department of Medical Oncology, Necmettin Erbakan University, Konya, Turkey
| | - Özgür Tanrıverdi
- grid.411861.b0000 0001 0703 3794Department of Medical Oncology, Muğla Sıtkı Koçman University, Muğla, Turkey
| | - İrfan Çiçin
- grid.411693.80000 0001 2342 6459Department of Medical Oncology, Trakya University, Edirne, Turkey
| | - Mehmet Ali Nahit Şendur
- grid.512925.80000 0004 7592 6297Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey
| | - Esin Oktay
- grid.34517.340000 0004 0595 4313Department of Medical Oncology, Adnan Menderes University, Aydın, Turkey
| | - İbrahim Vedat Bayoğlu
- grid.414850.c0000 0004 0642 8921Department of Medical Oncology, Marmara University Pendik Training and Research Hospital, Istanbul, Turkey
| | - Semra Paydaş
- grid.98622.370000 0001 2271 3229Department of Medical Oncology, Çukurova University, Adana, Turkey
| | - Adnan Aydıner
- grid.9601.e0000 0001 2166 6619Department of Medical Oncology, Istanbul University Instıtue of Oncology, Istanbul, Turkey
| | - Derya Kıvrak Salim
- grid.413819.60000 0004 0471 9397Department of Medical Oncology, Antalya Training and Research Hospital, Antalya, Turkey
| | - Çağlayan Geredeli
- Department of Medical Oncology, Okmeydanı Prof. Dr. Cemil Taşcıoğlu City Hospital, Istanbul, Turkey
| | - Tuğba Yavuzşen
- grid.21200.310000 0001 2183 9022Department of Medical Oncology, Dokuz Eylül University, İzmir, Turkey
| | - Mutlu Doğan
- grid.413794.cDepartment of Medical Oncology, UHS Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey
| | - İlhan Hacıbekiroğlu
- grid.49746.380000 0001 0682 3030Department of Medical Oncology, Sakarya University, Sakarya, Turkey
| |
Collapse
|
3
|
Karacin C, Oksuzoglu B, Demirci A, Keskinkılıç M, Baytemür NK, Yılmaz F, Selvi O, Erdem D, Avşar E, Paksoy N, Demir N, Göksu SS, Türker S, Bayram E, Çelebi A, Yılmaz H, Kuzu ÖF, Kahraman S, Gökmen İ, Sakin A, Alkan A, Nayır E, Uğraklı M, Acar Ö, Ertürk İ, Demir H, Aslan F, Sönmez Ö, Korkmaz T, Celayir ÖM, Karadağ İ, Kayıkçıoğlu E, Şakalar T, Öktem İN, Eren T, Urul E, Mocan EE, Kalkan Z, Yıldırım N, Ergün Y, Akagündüz B, Karakaya S, Kut E, Teker F, Demirel BÇ, Karaboyun K, Almuradova E, Ünal OÜ, Oyman A, Işık D, Okutur K, Öztosun B, Gülbağcı BB, Kalender ME, Şahin E, Seyyar M, Özdemir Ö, Selçukbiricik F, Kanıtez M, Dede İ, Gümüş M, Gökmen E, Yaren A, Menekşe S, Ebinç S, Aksoy S, İmamoğlu Gİ, Altınbaş M, Çetin B, Uluç BO, Er Ö, Karadurmuş N, Erdoğan AP, Artaç M, Tanrıverdi Ö, Çiçin İ, Şendur MAN, Oktay E, Bayoğlu İV, Paydaş S, Aydıner A, Salim DK, Geredeli Ç, Yavuzşen T, Doğan M, Hacıbekiroğlu İ. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy. BMC Cancer 2023; 23:136. [PMID: 36765293 PMCID: PMC9912535 DOI: 10.1186/s12885-023-10609-8] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2022] [Accepted: 02/03/2023] [Indexed: 02/12/2023] Open
Abstract
BACKGROUND There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists prefer in patients with disease progression under CDKi. In addition, we aimed to show the effectiveness of systemic treatments after CDKi and whether there is a survival difference between hormonal treatments (monotherapy vs. mTOR-based). METHODS A total of 609 patients from 53 centers were included in the study. Progression-free-survivals (PFS) of subsequent treatments (chemotherapy (CT, n:434) or endocrine therapy (ET, n:175)) after CDKi were calculated. Patients were evaluated in three groups as those who received CDKi in first-line (group A, n:202), second-line (group B, n: 153) and ≥ 3rd-line (group C, n: 254). PFS was compared according to the use of ET and CT. In addition, ET was compared as monotherapy versus everolimus-based combination therapy. RESULTS The median duration of CDKi in the ET arms of Group A, B, and C was 17.0, 11.0, and 8.5 months in respectively; it was 9.0, 7.0, and 5.0 months in the CT arm. Median PFS after CDKi was 9.5 (5.0-14.0) months in the ET arm of group A, and 5.3 (3.9-6.8) months in the CT arm (p = 0.073). It was 6.7 (5.8-7.7) months in the ET arm of group B, and 5.7 (4.6-6.7) months in the CT arm (p = 0.311). It was 5.3 (2.5-8.0) months in the ET arm of group C and 4.0 (3.5-4.6) months in the CT arm (p = 0.434). Patients who received ET after CDKi were compared as those who received everolimus-based combination therapy versus those who received monotherapy ET: the median PFS in group A, B, and C was 11.0 vs. 5.9 (p = 0.047), 6.7 vs. 5.0 (p = 0.164), 6.7 vs. 3.9 (p = 0.763) months. CONCLUSION Physicians preferred CT rather than ET in patients with early progression under CDKi. It has been shown that subsequent ET after CDKi can be as effective as CT. It was also observed that better PFS could be achieved with the subsequent everolimus-based treatments after first-line CDKi compared to monotherapy ET.
Collapse
Affiliation(s)
- Cengiz Karacin
- Department of Medical Oncology, UHS Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey.
| | - Berna Oksuzoglu
- grid.413794.cDepartment of Medical Oncology, UHS Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey
| | - Ayşe Demirci
- grid.49746.380000 0001 0682 3030Department of Medical Oncology, Sakarya University, Sakarya, Turkey
| | - Merve Keskinkılıç
- grid.21200.310000 0001 2183 9022Department of Medical Oncology, Dokuz Eylül University, İzmir, Turkey
| | | | - Funda Yılmaz
- grid.413794.cDepartment of Medical Oncology, UHS Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey
| | - Oğuzhan Selvi
- Department of Medical Oncology, Okmeydanı Prof. Dr. Cemil Taşcıoğlu City Hospital, Istanbul, Turkey
| | - Dilek Erdem
- Department of Medical Oncology, VM Medical Park Hospital, Samsun, Turkey
| | - Esin Avşar
- grid.413819.60000 0004 0471 9397Department of Medical Oncology, Antalya Training and Research Hospital, Antalya, Turkey
| | - Nail Paksoy
- grid.9601.e0000 0001 2166 6619Department of Medical Oncology, Istanbul University Instıtue of Oncology, Istanbul, Turkey
| | - Necla Demir
- grid.413290.d0000 0004 0643 2189Department of Medical Oncology, Acıbadem Hospital, Kayseri, Turkey
| | - Sema Sezgin Göksu
- grid.29906.34Department of Medical Oncology, Akdeniz University, Antalya, Turkey
| | - Sema Türker
- Department of Medical Oncology, Zonguldak Hospital, Zonguldak, Turkey
| | - Ertuğrul Bayram
- grid.98622.370000 0001 2271 3229Department of Medical Oncology, Çukurova University, Adana, Turkey
| | - Abdüssamet Çelebi
- grid.414850.c0000 0004 0642 8921Department of Medical Oncology, Marmara University Pendik Training and Research Hospital, Istanbul, Turkey
| | - Hatice Yılmaz
- grid.34517.340000 0004 0595 4313Department of Medical Oncology, Adnan Menderes University, Aydın, Turkey
| | - Ömer Faruk Kuzu
- grid.512925.80000 0004 7592 6297Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey
| | - Seda Kahraman
- grid.512925.80000 0004 7592 6297Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey
| | - İvo Gökmen
- grid.411693.80000 0001 2342 6459Department of Medical Oncology, Trakya University, Edirne, Turkey
| | - Abdullah Sakin
- grid.411781.a0000 0004 0471 9346Department of Medical Oncology, Istanbul Medipol University Bahçelievler Hospital, Istanbul, Turkey
| | - Ali Alkan
- grid.411861.b0000 0001 0703 3794Department of Medical Oncology, Muğla Sıtkı Koçman University, Muğla, Turkey
| | - Erdinç Nayır
- Mersin Medical Park Hospital, Department of Medical Oncology, Mersin, Turkey
| | - Muzaffer Uğraklı
- grid.411124.30000 0004 1769 6008Department of Medical Oncology, Necmettin Erbakan University, Konya, Turkey
| | - Ömer Acar
- grid.411688.20000 0004 0595 6052Department of Medical Oncology, Celal Bayar University, Manisa, Turkey
| | - İsmail Ertürk
- Department of Medical Oncology, Gülhane Training and Research Hospital, Ankara, Turkey
| | - Hacer Demir
- Department of Medical Oncology, Afyonkarahisar Health Sciences University Hospital, Afyonkarahisar, Turkey
| | - Ferit Aslan
- Department of Medical Oncology, Ankara Medical Park Hospital, Ankara, Turkey
| | - Özlem Sönmez
- grid.411117.30000 0004 0369 7552Department of Medical Oncology, Acıbadem University Maslak Hospital, Istanbul, Turkey
| | - Taner Korkmaz
- grid.411117.30000 0004 0369 7552Department of Medical Oncology, Acıbadem University Maslak Hospital, Istanbul, Turkey
| | - Özde Melisa Celayir
- grid.411117.30000 0004 0369 7552Department of Medical Oncology, Acıbadem University Maslak Hospital, Istanbul, Turkey
| | - İbrahim Karadağ
- grid.440466.40000 0004 0369 655XDepartment of Medical Oncology, Hitit University Hospital, Çorum, Turkey
| | - Erkan Kayıkçıoğlu
- grid.45978.37Department of Medical Oncology, Süleyman Demirel University Hospital, Isparta, Turkey
| | - Teoman Şakalar
- Department of Medical Oncology, Kahramanmaraş Necip Fazıl City Hospital, Kahramanmaraş, Turkey
| | - İlker Nihat Öktem
- Department of Medical Oncology, Ersin Arslan Training and Research Hospital, Gaziantep, Turkey
| | - Tülay Eren
- grid.413698.10000 0004 0419 0366Department of Medical Oncology, UHS Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
| | - Enes Urul
- grid.14442.370000 0001 2342 7339Department of Medical Oncology, Hacettepe University Instıtue of Oncology, Ankara, Turkey
| | - Eda Eylemer Mocan
- grid.7256.60000000109409118Department of Medical Oncology, Ankara University, Ankara, Turkey
| | - Ziya Kalkan
- grid.411690.b0000 0001 1456 5625Department of Medical Oncology, Dicle University, Diyarbakır, Turkey
| | - Nilgün Yıldırım
- grid.411320.50000 0004 0574 1529Department of Medical Oncology, Fırat University, Elazığ, Turkey
| | - Yakup Ergün
- Batman Training and Research Hospital, Batman, Turkey
| | - Baran Akagündüz
- grid.412176.70000 0001 1498 7262Department of Medical Oncology, Erzincan Binali Yıldırım University, Erzincan, Turkey
| | - Serdar Karakaya
- Department of Medical Oncology, Atatürk Pulmonary Diseases Hospital, Ankara, Turkey
| | - Engin Kut
- Department of Medical Oncology, Manisa City Hospital, Manisa, Turkey
| | - Fatih Teker
- grid.411549.c0000000107049315Department of Medical Oncology, Gaziantep University, Gaziantep, Turkey
| | - Burçin Çakan Demirel
- grid.411742.50000 0001 1498 3798Department of Medical Oncology, Pamukkale University, Denizli, Turkey
| | - Kubilay Karaboyun
- grid.412006.10000 0004 0369 8053Department of Medical Oncology, Namık Kemal University, Tekirdağ, Turkey
| | - Elvina Almuradova
- grid.8302.90000 0001 1092 2592Department of Medical Oncology, Ege University, İzmir, Turkey
| | - Olçun Ümit Ünal
- grid.414882.30000 0004 0643 0132UHS İzmir Tepecik Training and Research Hospital, İzmir, Turkey
| | - Abdilkerim Oyman
- grid.417018.b0000 0004 0419 1887Department of Medical Oncology, Ümraniye Training and Research Hospital, Istanbul, Turkey
| | - Deniz Işık
- Kocaeli Medical Park, Department of Medical Oncology, Kocaeli, Turkey
| | - Kerem Okutur
- grid.414854.8Department of Medical Oncology, Bahçelievler Memorial Hospital, Istanbul, Turkey
| | - Buğra Öztosun
- grid.411776.20000 0004 0454 921XDepartment of Medical Oncology, Istanbul Medeniyet University, Istanbul, Turkey
| | - Burcu Belen Gülbağcı
- grid.49746.380000 0001 0682 3030Department of Medical Oncology, Sakarya University, Sakarya, Turkey
| | | | - Elif Şahin
- grid.411105.00000 0001 0691 9040Department of Medical Oncology, Kocaeli University, Kocaeli, Turkey
| | - Mustafa Seyyar
- grid.411105.00000 0001 0691 9040Department of Medical Oncology, Kocaeli University, Kocaeli, Turkey
| | - Özlem Özdemir
- grid.414879.70000 0004 0415 690Xİzmir Bozyaka Training and Research Hospital, İzmir, Turkey
| | - Fatih Selçukbiricik
- grid.15876.3d0000000106887552Department of Medical Oncology, Koç University, Istanbul, Turkey
| | - Metin Kanıtez
- grid.413690.90000 0000 8653 4054Department of Medical Oncology, American Hospital, Istanbul, Turkey
| | - İsa Dede
- grid.14352.310000 0001 0680 7823Department of Medical Oncology, Mustafa Kemal University, Hatay, Turkey
| | - Mahmut Gümüş
- grid.411776.20000 0004 0454 921XDepartment of Medical Oncology, Istanbul Medeniyet University, Istanbul, Turkey
| | - Erhan Gökmen
- grid.8302.90000 0001 1092 2592Department of Medical Oncology, Ege University, İzmir, Turkey
| | - Arzu Yaren
- grid.411742.50000 0001 1498 3798Department of Medical Oncology, Pamukkale University, Denizli, Turkey
| | - Serkan Menekşe
- Department of Medical Oncology, Manisa City Hospital, Manisa, Turkey
| | - Senar Ebinç
- grid.411690.b0000 0001 1456 5625Department of Medical Oncology, Dicle University, Diyarbakır, Turkey
| | - Sercan Aksoy
- grid.14442.370000 0001 2342 7339Department of Medical Oncology, Hacettepe University Instıtue of Oncology, Ankara, Turkey
| | - Gökşen İnanç İmamoğlu
- grid.413698.10000 0004 0419 0366Department of Medical Oncology, UHS Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
| | - Mustafa Altınbaş
- grid.413698.10000 0004 0419 0366Department of Medical Oncology, UHS Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey
| | - Bülent Çetin
- grid.45978.37Department of Medical Oncology, Süleyman Demirel University Hospital, Isparta, Turkey
| | - Başak Oyan Uluç
- grid.411117.30000 0004 0369 7552Department of Medical Oncology, Acıbadem University Maslak Hospital, Istanbul, Turkey
| | - Özlem Er
- grid.411117.30000 0004 0369 7552Department of Medical Oncology, Acıbadem University Maslak Hospital, Istanbul, Turkey
| | - Nuri Karadurmuş
- Department of Medical Oncology, Gülhane Training and Research Hospital, Ankara, Turkey
| | - Atike Pınar Erdoğan
- grid.411688.20000 0004 0595 6052Department of Medical Oncology, Celal Bayar University, Manisa, Turkey
| | - Mehmet Artaç
- grid.411124.30000 0004 1769 6008Department of Medical Oncology, Necmettin Erbakan University, Konya, Turkey
| | - Özgür Tanrıverdi
- grid.411861.b0000 0001 0703 3794Department of Medical Oncology, Muğla Sıtkı Koçman University, Muğla, Turkey
| | - İrfan Çiçin
- grid.411693.80000 0001 2342 6459Department of Medical Oncology, Trakya University, Edirne, Turkey
| | - Mehmet Ali Nahit Şendur
- grid.512925.80000 0004 7592 6297Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey
| | - Esin Oktay
- grid.34517.340000 0004 0595 4313Department of Medical Oncology, Adnan Menderes University, Aydın, Turkey
| | - İbrahim Vedat Bayoğlu
- grid.414850.c0000 0004 0642 8921Department of Medical Oncology, Marmara University Pendik Training and Research Hospital, Istanbul, Turkey
| | - Semra Paydaş
- grid.98622.370000 0001 2271 3229Department of Medical Oncology, Çukurova University, Adana, Turkey
| | - Adnan Aydıner
- grid.9601.e0000 0001 2166 6619Department of Medical Oncology, Istanbul University Instıtue of Oncology, Istanbul, Turkey
| | - Derya Kıvrak Salim
- grid.413819.60000 0004 0471 9397Department of Medical Oncology, Antalya Training and Research Hospital, Antalya, Turkey
| | - Çağlayan Geredeli
- Department of Medical Oncology, Okmeydanı Prof. Dr. Cemil Taşcıoğlu City Hospital, Istanbul, Turkey
| | - Tuğba Yavuzşen
- grid.21200.310000 0001 2183 9022Department of Medical Oncology, Dokuz Eylül University, İzmir, Turkey
| | - Mutlu Doğan
- grid.413794.cDepartment of Medical Oncology, UHS Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey
| | - İlhan Hacıbekiroğlu
- grid.49746.380000 0001 0682 3030Department of Medical Oncology, Sakarya University, Sakarya, Turkey
| |
Collapse
|
4
|
Hizal M, Bilgin B, Paksoy N, Atcı MM, Kahraman S, Kılıçkap S, Güven DC, Keskinkılıç M, Ayhan M, Eren Ö, Mustafayev FNA, Yaman Ş, Bayram E, Ertürk İ, Özcan E, Korkmaz M, Akagündüz B, Erdem D, Telli TA, Aksoy A, Üskent N, Baytemür NK, Gülmez A, Aydın D, Şakalar T, Arak H, Tatlı AM, Ergün Y, Ak N, Ünal Ç, Özgün MA, Yalçın B, Öztop İ, Algın E, Sakin A, Aydıner A, Yumuk PF, Şendur MAN. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol 2022:10.1007/s00432-022-04252-2. [PMID: 36048274 DOI: 10.1007/s00432-022-04252-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2022] [Accepted: 08/02/2022] [Indexed: 10/14/2022]
Abstract
INTRODUCTION Alectinib is an effective second-generation ALK tyrosine kinase inhibitor (TKI) used in the first-line treatment of patients with advanced ALK-positive NSCLC. Recent studies demonstrated that the percentage of ALK-positive tumor cells in patient groups receiving crizotinib might affect outcomes. This study aimed to investigate whether the percentage of ALK-positive cells had a predictive effect in patients with advanced NSCLC who received first-line Alectinib as ALK-TKI. MATERIALS AND METHODS This retrospective study included patients with advanced-stage NSCLC who received alectinib as a first-line ALK-TKI and whose percentage of ALK-positive cells was determined by FISH at 27 different centers. Patients who received any ALK-TKI before alectinib were not included in the study. Patients were separated into two groups according to the median (40%) value of the percentage of ALK-positive cells (high-positive group ≥ 40% and low-positive group < 40%). The primary endpoint was PFS, and the secondary endpoints were OS, ORR, and PFS of the subgroups based on different threshold values for the percentage of ALK-positive cells. RESULTS 211 patients were enrolled (48.3% female, 51.7% male) to study. 37% (n = 78) of the patients had received chemotherapy previously. After a median of 19.4 months of follow-up, the median PFS was not reached in the high-positive group (n = 113), but it was 10.8 months in the low-positive group (n = 98) (HR 0.39; 95% CI 0.25-0.60, p < 0.001). The median OS in the high-positive group was not reached, whereas it was 22.8 months in the low-positive group (HR 0.37; 95% CI 0.22-0.63, p < 0.001). ORR was significantly higher in the high-positive group (87.2 vs. 68.5%; p = 0.002). According to the cut-off values of < 20%, 20-39%, 40-59%, and ≥ 60%, the median PFS was 4.5, 17.1, and 26 months, respectively, and could not be reached in the ≥ 60% group. CONCLUSION Our study demonstrated that the efficacy of alectinib varies significantly across patient subgroups with different percentages of ALK-positive cells. If these findings are prospectively validated, the percentage of ALK-positive cells may be used as a stratification factor in randomized trials comparing different ALK-TKIs.
Collapse
Affiliation(s)
- Mutlu Hizal
- Department of Medical Oncology, Ankara City Hospital, Bilkent Caddesi, No:1, 06800, Ankara, Turkey.
| | - Burak Bilgin
- Department of Medical Oncology, Atatürk Chest Disease and Chest Surgery Education and Research Hospital, Ankara, Turkey
| | - Nail Paksoy
- Department of Medical Oncology, İstanbul Faculty of Medicine, İstanbul University, Istanbul, Turkey
| | - Muhammed Mustafa Atcı
- Department of Medical Oncology, İstanbul Prof. Cemil Taşçıoglu City Hospital, Istanbul, Turkey
| | - Seda Kahraman
- Department of Medical Oncology, Faculty of Medicine, Yıldırım Beyazıt University, Ankara, Turkey
| | - Saadettin Kılıçkap
- Department of Medical Oncology, Faculty of Medicine, Ankara Liv Hospital, İstinye University, Ankara, Turkey
| | - Deniz Can Güven
- Department of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
| | - Merve Keskinkılıç
- Department of Medical Oncology, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey
| | - Murat Ayhan
- Department of Medical Oncology, Kartal Dr. Lütfi Kırdar City Hospital, Istanbul, Turkey
| | - Önder Eren
- Department of Medical Oncology, Faculty of Medicine, Selçuk University, Konya, Turkey
| | - Fatma Nihan Akkoç Mustafayev
- Department of Medical Oncology, Sultan 2. Abdülhamid Han Education and Research Hospital, University of Health Sciences, Istanbul, Turkey
| | - Şebnem Yaman
- Department of Medical Oncology, Atatürk Chest Disease and Chest Surgery Education and Research Hospital, Ankara, Turkey
| | - Ertuğrul Bayram
- Department of Medical Oncology, Faculty of Medicine, Çukurova University, Adana, Turkey
| | - İsmail Ertürk
- Department of Medical Oncology, Ankara Gülhane Education and Research Hospital, Ankara, Turkey
| | - Erkan Özcan
- Department of Medical Oncology, Faculty of Medicine, Trakya University, Edirne, Turkey
| | - Mustafa Korkmaz
- Department of Medical Oncology, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey
| | - Baran Akagündüz
- Department of Medical Oncology, Erzincan Mengücek Gazi Education and Research Hospital, Erzincan, Turkey
| | - Dilek Erdem
- Department of Medical Oncology, Samsun Medical Park Hospital, Samsun, Turkey
| | - Tuğba Akın Telli
- Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey
| | - Asude Aksoy
- Department of Medical Oncology, Faculty of Medicine, Fırat University, Elazıg, Turkey
| | - Necdet Üskent
- Department of Medical Oncology, Anadolu Medical Center, Kocaeli, Turkey
| | | | - Ahmet Gülmez
- Department of Medical Oncology, Faculty of Medicine, İnönü University, Malatya, Turkey
| | - Dinçer Aydın
- Department of Medical Oncology, Kocaeli Derince Education and Research Hospital, Kocaeli, Turkey
| | - Teoman Şakalar
- Department of Medical Oncology, Necip Fazıl City Hospital, Kahramanmaras, Turkey
| | - Hacı Arak
- Department of Medical Oncology, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey
| | - Ali Murat Tatlı
- Department of Medical Oncology, Faculty of Medicine, Akdeniz University, Antalya, Turkey
| | - Yakup Ergün
- Department of Medical Oncology, Batman Education and Research Hospital, Batman, Turkey
| | - Naziye Ak
- Department of Medical Oncology, Yozgat City Hospital, Yozgat, Turkey
| | - Çağlar Ünal
- Department of Medical Oncology, Gayrettepe Florence Nightingale Hospital, Istanbul, Turkey
| | - Mehmet Alpaslan Özgün
- Department of Medical Oncology, Sultan 2. Abdülhamid Han Education and Research Hospital, University of Health Sciences, Istanbul, Turkey
| | - Bülent Yalçın
- Department of Medical Oncology, Faculty of Medicine, Yıldırım Beyazıt University, Ankara, Turkey
| | - İlhan Öztop
- Department of Medical Oncology, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey
| | - Efnan Algın
- Department of Medical Oncology, Ankara City Hospital, University of Health Sciences, Ankara, Turkey
| | - Abdullah Sakin
- Department of Medical Oncology, İstanbul Prof. Cemil Taşçıoglu City Hospital, Istanbul, Turkey
| | - Adnan Aydıner
- Department of Medical Oncology, İstanbul Faculty of Medicine, İstanbul University, Istanbul, Turkey
| | - Perran Fulden Yumuk
- Department of Medical Oncology, Faculty of Medicine, Koç University, Istanbul, Turkey.,Department of Medical Oncology, American Hospital, Istanbul, Turkey
| | - Mehmet Ali Nahit Şendur
- Department of Medical Oncology, Faculty of Medicine, Yıldırım Beyazıt University, Ankara, Turkey
| |
Collapse
|
5
|
Hizal M, Bilgin B, Paksoy N, Kılıçkap S, Atcı MM, Kahraman S, Keskinkılıç M, Bilgetekin İ, Ayhan M, Tural D, Eren Ö, Akkoç Mustafayev FN, Yaman Ş, Tatlı AM, Bayram E, Kutlu Y, Ertürk İ, Özcan E, Gülmez A, Korkmaz M, Akagündüz B, Erdem D, Telli TA, Aksoy A, Üskent N, İriağaç Y, Baytemür NK, Aydın D, Şakalar T, Arak H, Selçukbiricik F, Ergün Y, Korkmaz T, Ak N, Ünal Ç, Akdeniz N, Özgün MA, Öksüzoğlu B, Yalçın B, Öztop İ, Algın E, Sakin A, Aydıner A, Yumuk PF, Nahit Şendur MA. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol 2022; 18:2573-2582. [PMID: 35734870 DOI: 10.2217/fon-2022-0083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Aims: In this multicenter study, the authors aimed to determine the real-life efficacy and safety of first-line alectinib. Materials & methods: This retrospective trial included advanced-stage, ALK-positive non-small-cell lung cancer patients who were treated with first-line alectinib in terms of ALK-tyrosine kinase inhibitors, regardless of previous chemotherapy. The co-primary end points were progression-free survival both for all patients and for the treatment-naive population. The secondary end points were overall response rate, overall survival, rate of CNS progression and safety. Results & conclusion: A total of 274 patients (n = 177 for treatment-naive patients) were enrolled in the study. The median progression-free survival was 26 and 28.8 months for all patients and the treatment-naive group, respectively. The overall response rate, CNS progression rate and 1-year overall survival ratio were 77.9, 12.4 and 77%. Alectinib is a highly effective therapy with a favorable safety profile.
Collapse
Affiliation(s)
- Mutlu Hizal
- Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey
| | - Burak Bilgin
- Atatürk Chest Disease & Chest Surgery Education & Research Hospital, Department of Medical Oncology, Ankara, Turkey
| | - Nail Paksoy
- Department of Medical Oncology, İstanbul Faculty of Medicine, İstanbul University, Istanbul, Turkey
| | - Saadettin Kılıçkap
- Department of Medical Oncology, İstinye University Faculty of Medicine, Ankara Liv Hospital, Ankara, Turkey
| | - Muhammed Mustafa Atcı
- Department of Medical Oncology, İstanbul Prof. Cemil Taşçıoglu City Hospital, Istanbul, Turkey
| | - Seda Kahraman
- Department of Medical Oncology, Yıldırım Beyazıt University Faculty of Medicine, Ankara, Turkey
| | - Merve Keskinkılıç
- Department of Medical Oncology, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey
| | - İrem Bilgetekin
- Department of Medical Oncology, Abdurrahman Yurtaslan Ankara Onkoloji Education & Research Hospital, Ankara, Turkey
| | - Murat Ayhan
- Department of Medical Oncology, Kartal Dr. Lütfi Kırdar City Hospital, Istanbul, Turkey
| | - Deniz Tural
- Department of Medical Oncology, Bakırköy Dr. Sadi Konuk Education & Research Hospital, Istanbul, Turkey
| | - Önder Eren
- Department of Medical Oncology, Selçuk University Faculty of Medicine, Konya, Turkey
| | - Fatma Nihan Akkoç Mustafayev
- Department of Medical Oncology, University of Health Sciences, Sultan 2. Abdülhamid Han Education & Research Hospital, Istanbul, Turkey
| | - Şebnem Yaman
- Atatürk Chest Disease & Chest Surgery Education & Research Hospital, Department of Medical Oncology, Ankara, Turkey
| | - Ali Murat Tatlı
- Department of Medical Oncology, Akdeniz University Faculty of Medicine, Antalya, Turkey
| | - Ertuğrul Bayram
- Department of Medical Oncology, Çukurova University Faculty of Medicine, Adana, Turkey
| | - Yasin Kutlu
- Department of Medical Oncology, İstanbul Medipol University Faculty of Medicine, Istanbul, Turkey
| | - İsmail Ertürk
- Department of Medical Oncology, Ankara Gülhane Education & Research Hospital, Ankara, Turkey
| | - Erkan Özcan
- Department of Medical Oncology, Trakya University Faculty of Medicine, Edirne, Turkey
| | - Ahmet Gülmez
- Department of Medical Oncology, İnönü University Faculty of Medicine, Malatya, Turkey
| | - Mustafa Korkmaz
- Department of Medical Oncology, Necmettin Erbakan University, Meram Faculty of Medicine, Konya, Turkey
| | - Baran Akagündüz
- Department of Medical Oncology, Erzincan Mengücek Gazi Education & Research Hospital, Erzincan, Turkey
| | - Dilek Erdem
- Department of Medical Oncology, Samsun Medical Park Hospital, Samsun, Turkey
| | - Tuğba Akın Telli
- Department of Medical Oncology, Marmara University Faculty of Medicine, Istanbul, Turkey
| | - Asude Aksoy
- Department of Medical Oncology, Fırat University Faculty of Medicine, Elazıg, Turkey
| | - Necdet Üskent
- Department of Medical Oncology, Anadolu Medical Center, Kocaeli, Turkey
| | - Yakup İriağaç
- Department of Medical Oncology, Tekirdağ Namık Kemal University Faculty of Medicine, Tekirdag, Turkey
| | | | - Dinçer Aydın
- Department of Medical Oncology, Kocaeli Derince Education & Research Hospital, Kocaeli, Turkey
| | - Teoman Şakalar
- Department of Medical Oncology, Necip Fazıl City Hospital, Kahramanmaras, Turkey
| | - Hacı Arak
- Gaziantep University Faculty of Medicine, Department of Medical Oncology, Gaziantep, Turkey
| | - Fatih Selçukbiricik
- Department of Medical Oncology, Koç University Faculty of Medicine, Istanbul, Turkey
| | - Yakup Ergün
- Department of Medical Oncology, Batman Education & Research Hospital, Batman, Turkey
| | - Taner Korkmaz
- Department of Medical Oncology, Acıbadem Maslak Hospital, Istanbul, Turkey
| | - Naziye Ak
- Department of Medical Oncology, Yozgat City Hospital, Yozgat, Turkey
| | - Çağlar Ünal
- Department of Medical Oncology, Gayrettepe Florence Nightingale Hospital, Istanbul, Turkey
| | - Nadiye Akdeniz
- Department of Medical Oncology, Adıyaman University, Education & Research Hospital, Adıyaman, Turkey
| | - Mehmet Alpaslan Özgün
- Department of Medical Oncology, University of Health Sciences, Sultan 2. Abdülhamid Han Education & Research Hospital, Istanbul, Turkey
| | - Berna Öksüzoğlu
- Department of Medical Oncology, Abdurrahman Yurtaslan Ankara Onkoloji Education & Research Hospital, Ankara, Turkey
| | - Bülent Yalçın
- Department of Medical Oncology, Yıldırım Beyazıt University Faculty of Medicine, Ankara, Turkey
| | - İlhan Öztop
- Department of Medical Oncology, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey
| | - Efnan Algın
- Department of Medical Oncology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey
| | - Abdullah Sakin
- Department of Medical Oncology, İstanbul Prof. Cemil Taşçıoglu City Hospital, Istanbul, Turkey
| | - Adnan Aydıner
- Department of Medical Oncology, İstanbul Faculty of Medicine, İstanbul University, Istanbul, Turkey
| | - Perran Fulden Yumuk
- Department of Medical Oncology, Koç University Faculty of Medicine, Istanbul, Turkey.,Department of Medical Oncology, American Hospital, Istanbul, Turkey
| | - Mehmet Ali Nahit Şendur
- Department of Medical Oncology, Yıldırım Beyazıt University Faculty of Medicine, Ankara, Turkey
| |
Collapse
|
6
|
Gürbüz M, Kutlu Y, Akkuş E, Köksoy EB, Köse N, Öven BB, Uluç BO, Demiray AG, Erdem D, Demir B, Turhal NS, Üskent N, Akbaş S, Selçukbiricik F, İnal A, Bilici A, Ölmez ÖF, Çabuk D, Ünal Ç, Hızal M, Şendur MAN, Korkmaz M, Karadurmuş N, Ertürk İ, Göksu SS, Tatlı AM, Güven DC, Kılıçkap S, Paksoy N, Aydıner A, Çınkır HY, Özkul Ö, Öztürk A, Ballı S, Kemal Y, Erdoğan AP, Er Ö, Yumuk PF, Demirkazık A. Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group. J Cancer Res Clin Oncol 2022; 148:3547-3555. [PMID: 35689097 DOI: 10.1007/s00432-022-04087-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2022] [Accepted: 05/22/2022] [Indexed: 11/30/2022]
Abstract
PURPOSE Atezolizumab has been shown to be effective and safe in randomized trial in the first-line treatment of extensive-stage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In this study, we aimed to determine the real-life efficacy and safety of atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage SCLC. METHODS This trial is a retrospective multicenter study of the Turkish Oncology Group, which included extensive-stage SCLC patients who received atezolizumab combined with chemotherapy in a first-line treatment. The characteristics of the patients, treatment and response rates, and PFS and OS are presented. Factors associated with PFS and OS were analyzed by univariate and multivariate analysis. RESULTS A total of 213 patients at the 30 oncology centers were included. The median number of chemotherapy cycle was 5 (1-8) and atezolizumab cycle was 7 (1-32). After median 11.9 months of follow-up, median PFS and OS was 6.8 months (95%CI 5.7-7.8), and 11.9 months (95%CI 11-12.7), respectively. The ORR was 61.9%. ECOG-PS (p = 0.002) and number of metastatic sites (p = 0.001) were associated with PFS and pack-year of smoking (p = 0.05), while ECOG-PS (p = 0.03) and number of metastatic sites (p = 0.001) were associated with OS. Hematological side effects were common and toxicities were manageable. CONCLUSION This real-life data confirm the efficacy and safety of atezolizumab in combination with chemotherapy in first-line treatment of extensive-stage SCLC.
Collapse
Affiliation(s)
- Mustafa Gürbüz
- Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey.
| | - Yasin Kutlu
- Department of Medical Oncology, Faculty of Medicine, İstanbul Medipol University, Istanbul, Turkey
| | - Erman Akkuş
- Department of Internal Medicine, Faculty of Medicine, Ankara University, Ankara, Turkey
| | - Elif Berna Köksoy
- Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey
| | - Naziyet Köse
- Department of Medical Oncology, Memorial Ankara Hospital, Ankara, Turkey
| | - Bala Başak Öven
- Department of Medical Oncology, Faculty of Medicine, Bahçeşehir University, Göztepe Medical Park Hospital, Istanbul, Turkey
| | - Başak Oyan Uluç
- Department of Medical Oncology, Acıbadem Altunizade Hospital, Istanbul, Turkey
| | - Atike Gökçen Demiray
- Department of Medical Oncology, Faculty of Medicine, Pamukkale University, Denizli, Turkey
| | - Dilek Erdem
- Department of Medical Oncology, Samsun Medical Park Hospital, Samsun, Turkey
| | - Bilgin Demir
- Department of Medical Oncology, Faculty of Medicine, Aydın Adnan Menderes University, Aydın, Turkey
| | | | - Necdet Üskent
- Department of Medical Oncology, Anadolu Medical Center, Kocaeli, Turkey
| | - Sinem Akbaş
- Department of Medical Oncology, Koç University Hospital, Istanbul, Turkey
| | | | - Ali İnal
- Department of Medical Oncology, Mersin City Hospital, Mersin, Turkey
| | - Ahmet Bilici
- Department of Medical Oncology, Faculty of Medicine, İstanbul Medipol University, Istanbul, Turkey
| | - Ömer Fatih Ölmez
- Department of Medical Oncology, Faculty of Medicine, İstanbul Medipol University, Istanbul, Turkey
| | - Devrim Çabuk
- Department of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey
| | - Çağlar Ünal
- Department of Medical Oncology, Gayrettepe Florence Nightingale Hospital, Istanbul, Turkey
| | - Mutlu Hızal
- Department of Medical Oncology, Faculty of Medicine, Yıldırım Beyazıt University, Ankara, Turkey
| | - Mehmet Ali Nahit Şendur
- Department of Medical Oncology, Faculty of Medicine, Yıldırım Beyazıt University, Ankara, Turkey
| | - Mustafa Korkmaz
- Meram Faculty of Medicine, Department of Medical Oncology, Necmettin Erbakan University, Konya, Turkey
| | - Nuri Karadurmuş
- Department of Medical Oncology, University of Health Sciences, Gülhane Training and Research Hospital, Ankara, Turkey
| | - İsmail Ertürk
- Department of Medical Oncology, University of Health Sciences, Gülhane Training and Research Hospital, Ankara, Turkey
| | - Sema Sezgin Göksu
- Department of Medical Oncology, Faculty of Medicine, Akdeniz University, Antalya, Turkey
| | - Ali Murat Tatlı
- Department of Medical Oncology, Faculty of Medicine, Akdeniz University, Antalya, Turkey
| | - Deniz Can Güven
- Department of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
| | - Saadettin Kılıçkap
- Department of Medical Oncology, Faculty of Medicine, İstinye University, Liv Ankara Hospital, Ankara, Turkey
| | - Nail Paksoy
- Department of Medical Oncology, Faculty of Medicine, İstanbul University, Istanbul, Turkey
| | - Adnan Aydıner
- Department of Medical Oncology, Faculty of Medicine, İstanbul University, Istanbul, Turkey
| | - Havva Yeşil Çınkır
- Department of Medical Oncology, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey
| | - Özlem Özkul
- Department of Medical Oncology, Bağcılar Training and Research Hospital, Istanbul, Turkey
| | - Akın Öztürk
- Department of Medical Oncology, Süreyyapaşa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey
| | - Sevinç Ballı
- Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey
| | - Yasemin Kemal
- Department of Medical Oncology, Samsun Medical Park Hospital, Samsun, Turkey
| | - Atike Pınar Erdoğan
- Department of Medical Oncology, Manisa Celal Bayar University Faculty of Medicine, Manisa, Turkey
| | - Özlem Er
- Department of Medical Oncology, Maslak Acıbadem Hospital, Istanbul, Turkey
| | | | - Ahmet Demirkazık
- Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey
| |
Collapse
|
7
|
Yekedüz E, Ertürk İ, Tural D, Karadurmuş N, Karakaya S, Hızal M, Arıkan R, Arslan Ç, Taban H, Küçükarda A, Öztaş NŞ, Sever ÖN, Uçar G, Can O, Nahit Şendur MA, Demirci U, Kılıçkap S, Çiçin İ, Öksüzoğlu B, Özgüroğlu M, Ürün Y. Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database. Future Oncol 2021; 17:4861-4869. [PMID: 34726480 DOI: 10.2217/fon-2021-0717] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Aim: The authors present real-world data on the efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC). Methods: The Turkish Oncology Group Kidney Cancer Consortium (TKCC) database includes patients with mRCC from 13 cancer centers in Turkey. Patients with mRCC treated with nivolumab in the second line and beyond were extracted from the TKCC database. Results: A total of 173 patients were included. The rates of patients treated with nivolumab in the second, third, fourth and fifth lines were 47.4%, 32.4%, 14.5% and 5.7%, respectively. The median overall survival and progression-free survival were 24.2 months and 9.6 months, respectively. Nivolumab was discontinued owing to adverse events in 11 (6.4%) patients. Conclusion: Nivolumab was effective in patients with mRCC and no new safety signal was observed.
Collapse
Affiliation(s)
- Emre Yekedüz
- Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, 06590, Turkey.,Cancer Research Institute, Ankara University, Ankara, 06590, Turkey
| | - İsmail Ertürk
- Department of Medical Oncology, Gülhane Education & Research Hospital, University of Health Sciences, Ankara, 06010, Turkey
| | - Deniz Tural
- Department of Medical Oncology, Bakirköy Dr. Sadi Konuk Training & Research Hospital, University of Health Sciences, İstanbul, 34147, Turkey
| | - Nuri Karadurmuş
- Department of Medical Oncology, Gülhane Education & Research Hospital, University of Health Sciences, Ankara, 06010, Turkey
| | - Serdar Karakaya
- Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Education & Research Hospital, University of Health Sciences, Ankara, 06200, Turkey
| | - Mutlu Hızal
- Department of Medical Oncology, Ankara City Hospital, University of Health Sciences, Ankara, 06800, Turkey
| | - Rukiye Arıkan
- Department of Medical Oncology, Marmara University, İstanbul, 34899, Turkey
| | - Çağatay Arslan
- Department of Medical Oncology, İzmir University of Economics, İzmir, 35575, Turkey
| | - Hakan Taban
- Department of Medical Oncology, Hacettepe University, Ankara, 06230, Turkey
| | - Ahmet Küçükarda
- Department of Medical Oncology, Trakya University, Edirne, 22020, Turkey
| | - Nihan Şentürk Öztaş
- Division of Medical Oncology, İstanbul University-Cerrahpaşa, İstanbul, 34098, Turkey
| | - Özlem Nuray Sever
- Department of Medical Oncology, Gaziantep University, Gaziantep, 27070, Turkey
| | - Gökhan Uçar
- Department of Medical Oncology, Ankara City Hospital, University of Health Sciences, Ankara, 06800, Turkey
| | - Orçun Can
- Department of Medical Oncology, Prof. Dr. Cemil Taşçıoğlu City Hospital, University of Health Sciences, İstanbul, 34384, Turkey
| | | | - Umut Demirci
- Department of Medical Oncology, Üsküdar University, Memorial Ankara Hospital, Ankara, 06520, Turkey
| | - Saadettin Kılıçkap
- Department of Medical Oncology, Hacettepe University, Ankara, 06230, Turkey.,Department of Medical Oncology, İstinye University, İstanbul, 34010, Turkey
| | - İrfan Çiçin
- Department of Medical Oncology, Trakya University, Edirne, 22020, Turkey
| | - Berna Öksüzoğlu
- Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Education & Research Hospital, University of Health Sciences, Ankara, 06200, Turkey
| | - Mustafa Özgüroğlu
- Division of Medical Oncology, İstanbul University-Cerrahpaşa, İstanbul, 34098, Turkey
| | - Yüksel Ürün
- Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, 06590, Turkey.,Cancer Research Institute, Ankara University, Ankara, 06590, Turkey
| |
Collapse
|
8
|
Ertürk İ, Sertoğlu E, Yeşildal F, Acar R, Özgürtaş T, Sağlam K. Angiostatin levels in diabetes mellitus patients receiving insulin treatment: associations
with laboratory findings, comorbidities, and medications. Turk J Med Sci 2018; 48:1192-1199. [PMID: 30541246 DOI: 10.3906/sag-1802-130] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
Background/aim The clinical effect of angiostatin in diabetes mellitus (DM) patients receiving insulin is a meaningful gap in the
literature. In this study, we aimed to show the levels and the clinical significance of angiostatin in DM patients receiving insulin. Materials and methods This is a case-control study. Serum angiostatin levels were determined by ELISA. A total of 83 people consisting
of healthy subjects (n = 36) and patients with a diagnosis of DM receiving insulin therapy (n = 47) were included in this study. Results The mean angiostatin levels of the DM group were significantly higher than those of the control group (86.0 ± 68.1 ng/mL
and 58.0 ± 22.4 ng/mL, respectively; P = 0.011). Significantly lower angiostatin levels were determined in the DM patients receiving
metformin with respect to those not receiving metformin (97.2 ± 74.4 ng/mL and 49.3 ± 7.0 ng/mL, respectively; P = 0.021). Significantly
higher levels of angiostatin were observed among the DM patients using a beta-blocker (BB) than the DM patients not using a BB (115.5
± 78.71 ng/mL and 73.44 ± 60.08 ng/mL, respectively; p = 0.029). Conclusion This is the first study evaluating and demonstrating the serum angiostatin levels in DM patients receiving insulin. Further
studies are required to understand the effect of angiostatin in diabetics and the effect of medications on angiogenesis in these patients.
Collapse
Affiliation(s)
- İsmail Ertürk
- Department of Internal Medicine, Gülhane School of Medicine, University of Health Sciences, Ankara, Turkey
| | - Erdim Sertoğlu
- Department of Biochemistry, Gülhane School of Medicine, University of Health Sciences, Ankara, Turkey
| | - Fatih Yeşildal
- Department of Medical Biochemistry, İstanbul Medeniyet University, Göztepe Training and Research Hospital, İstanbul, Turkey
| | - Ramazan Acar
- Department of Internal Medicine, Gülhane School of Medicine, University of Health Sciences, Ankara, Turkey
| | - Taner Özgürtaş
- Department of Biochemistry, Gülhane School of Medicine, University of Health Sciences, Ankara, Turkey
| | - Kenan Sağlam
- Department of Internal Medicine, Gülhane School of Medicine, University of Health Sciences, Ankara, Turkey
| |
Collapse
|
9
|
Karadurmuş N, Ertürk İ. Which is the best for cancer treatment? Surgery or chemotherapy. Journal of Oncological Sciences 2017. [DOI: 10.1016/j.jons.2017.02.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|